Amsterdam’s Ellogon secures €1M to advance personalised immunotherapy innovation
Amsterdam-based Ellogon, a company working on personalising immunotherapy with data and algorithms, announced that it has secured €1M in fresh funding from ROM InWest and UvA Ventures Holding.